IMA seeks Center to ensure Covaxin availability if cocktail policy for booster is adopted
IMA has also welcomed the government's decision to inoculate children between 15 to 18 years of age.
New Delhi: The Indian Medical Association (IMA) on Sunday said that the Centre should ensure the large-scale availability of Covaxin if a mixed match policy is adopted for booster doses for healthcare workers, as majority of the people have taken Covishield as their first and second doses.
"On behalf of the frontline and healthcare workers, we hail the announcement of the Prime Minister for the precautionary booster dose for healthcare and frontline workers. It is the right step as the imminent third wave by the new variant is a matter of concern. Omicron is at our doorstep and we need to protect our healthcare and frontline workers in all possible ways", the IMA said in a statement.
Also Read: CDSCO approves extension of Covaxin shelf life up to 12 months
On the ongoing RDA strike which has hit all the medical services in the national capital, the IMA said that the issue of expediting PG counseling is the need of the hour to increase manpower ahead of the looming third wave threat.
The infrastructure without manpower is a futile measure, it added.
The association has also welcomed the government's decision to inoculate children between 15-18 years of age.
J.A. Jayalal, National President of the IMA, said, "The IMA also welcomes the much-awaited decision of vaccination for children from January 3. At this moment of reopening of schools, this will be the welcome step to bring additional safety to children. The vaccination process for children must be handled with much more care and constant monitoring and surveillance must be ensured."
Also Read: Can Covaxin protect against Omicron? Bharat Biotech to examine
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd